A Danish nationwide registry study found lower short-term relapse rates and few confirmed disability-worsening events among ...
A Japanese study found that higher postpartum depression scores were associated with greater mother-infant bonding ...
E shows durable abemaciclib benefit across N1 high-risk, N2 and N3 HR+/HER2− early breast cancer after 76.8 months of follow-up.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...
Patients with seronegative rheumatoid arthritis experience a higher prevalence of extra-articular manifestations than seropositive patients.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts-including five rapid oral ...
Shares of Zentalis Pharmaceuticals (ZNTL) gained on Monday after the cancer drug developer announced mid-stage trial data ...
Cyrano Therapeutics' Phase 2 trial showed statistically significant smell improvement in under-60 patients on high-dose ...
Zydus Therapeutics Inc, a wholly owned subsidiary of Zydus Lifesciences Limited, has presented new findings from its ...
At VIVA 2026, the Vascular InterVentional Advances conference, William A. Gray, MD, presented findings from a subgroup analysis ...
Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results